Jubilant Pharmova Limited (BOM:530019)
India · Delayed Price · Currency is INR 1,194.55
-8.90 (-0.74%)
At close: Jul 16, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
Radiopharma | 30.01B | Log In | Log In | Log In | Log In | Upgrade |
Radiopharma Growth | 17.59% | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Organisation - Sterile Injectables | 11.17B | Log In | Log In | Log In | Log In | Upgrade |
Contract Development and Manufacturing Organisation - Sterile Injectables Growth | -3.26% | Log In | Log In | Log In | Log In | Upgrade |
Contract Research, and Development and Manufacturing Organisation | 10.93B | Log In | Log In | Log In | Log In | Upgrade |
Contract Research, and Development and Manufacturing Organisation Growth | -7.74% | Log In | Log In | Log In | Log In | Upgrade |
Generics | 7.75B | Log In | Log In | Log In | Log In | Upgrade |
Generics Growth | 1.71% | Log In | Log In | Log In | Log In | Upgrade |
Allergy Immunotherapy | 6.79B | Log In | Log In | Log In | Log In | Upgrade |
Allergy Immunotherapy Growth | 12.58% | Log In | Log In | Log In | Log In | Upgrade |
Management Services | 383.00M | Log In | Log In | Log In | Log In | Upgrade |
Management Services Growth | 75.63% | Log In | Log In | Log In | Log In | Upgrade |
Proprietary Novel Drugs | - | Log In | Log In | Log In | Log In | Upgrade |
Proprietary Novel Drugs Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Research and Development | - | Log In | Log In | Log In | Log In | Upgrade |
Contract Research and Development Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Life Science Ingredients | - | Log In | Log In | Log In | Log In | Upgrade |
Life Science Ingredients Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Drug Discovery and Development Solutions | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | 2016 - 2018 |
Americas and Europe | 60.12B | Log In | Log In | Log In | Log In | Upgrade |
Americas and Europe Growth | 7.48% | Log In | Log In | Log In | Log In | Upgrade |
Rest of the World | 4.99B | Log In | Log In | Log In | Log In | Upgrade |
Rest of the World Growth | 0.25% | Log In | Log In | Log In | Log In | Upgrade |
India | 1.92B | Log In | Log In | Log In | Log In | Upgrade |
India Growth | 0.70% | Log In | Log In | Log In | Log In | Upgrade |
China | - | Log In | Log In | Log In | Log In | Upgrade |
China Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Global | - | Log In | Log In | Log In | Log In | Upgrade |